-
Claudin 18.2 track is in full swing! O'Sai Kang, Ke Ji, Rong Chang... Who will break through
Time of Update: 2022-09-21
From: Insight Database Web Aosaikang's self-developed monoclonal ANTIBODy ASKB589, which uses defulose technology in molecular design and cell line components, further enhances its ADCC and CDC functions, and is currently conducting phase I and II clinical trials for the treatment of gastric and pancreatic cancers, and preliminary data show good tolerance.
-
Fragile X protein regulates hippocampal GABA-A receptors
Time of Update: 2022-08-15
. In the work published in Cell Reports , Dr. Vitaly Klyachko, professor of cell biology and physiology at the University of Washington School of Medicine, said: "It is thought that because the fragile X chromosome is associated with the loss of a single protein, it is a simple disease , we can understand and fix quickly .
-
Featured Exhibition Area - Helping Jinan Bio-Fermentation Exhibition
Time of Update: 2022-08-12
, to create a highly international social bio-industry ecosystem; Product Range Upstream equipment area: Medium preparation equipment, air purification and sterilization equipment, bioreactor, ventilation fermentation equipment, anaerobic fermentation equipment, animal and plant cell culture equipment and enzyme reactor, microbial cell crushing equipment, supercritical extraction, ion exchange equipment, evaporation and crystallization Equipment, material handling equipment and product packaging equipment, bioengineering water supply and refrigeration systems and equipment .
-
Hefei Research Institute has developed a new type of tropomyosin receptor kinase inhibitor
Time of Update: 2022-06-22
NTRK gene fusion occurs in a variety of solid tumors in adults and children, including breast cancer, colorectal cancer, non-small cell lung cancer, and various sarcomas .
-
Innovent's FGFR inhibitor approved for marketing
Time of Update: 2022-05-25
Article source: Medical Cube InfoAuthor: infoOn April 6, the NMPA approved the marketing application of Innovent Bio-Fibroblast Growth Factor Receptor (FGFR) 1/2/3 inhibitor pemigatinib for at least one prior systemic therapy , and adult patients with advanced, metastatic, or unresectable cholangiocarcinoma with confirmed FGFR2 fusions or rearrangements .
-
Nat Med: Bloodborne tumor mutational burden as a biomarker for atezolizumab therapy in non-small cell lung cancer
Time of Update: 2022-05-21
In a study published today in the top medical journal Nature Medicine to prospectively assess blood TMB (bTMB), researchers conducted the B-F1RST trial (NCT02848651), an open-label 2 Phase III clinical trial evaluating bTMB as a predictive biomarker for first-line atezolizumab monotherapy in locally advanced or metastatic stage IIIB-IVB non-small cell lung cancer (n=152) .
-
Cardiovasc Diabetol: Elevated IL-12/23p40 Levels as a Potential Indicator of Heart Rate Variability Dysfunction in Type 2 Diabetes
Time of Update: 2022-01-23
In conclusion, this study found a strong correlation between cardiac function and serum markers, especially IL-12/IL-23p40, suggesting that systemic alterations in proinflammatory cytokines, endothelial cell, and lymphatic function affect overall cardiovascular function .
-
New anti-tumor drug outbreak: more than 70 products have been approved for clinical use, and Hengrui and Junshi performed well
Time of Update: 2021-12-29
Since November, there have been more than 100 clinically approved new drugs in China, of which nearly seven have become anti-tumor drugs, involving pharmaceutical companies such as Hengrui and Junshi .
-
Express targets a variety of solid tumors, and clinical trials of allogeneic CAR-T therapy have been approved by the FDA
Time of Update: 2021-12-28
▎ WuXi AppTec content team editor today, Poseida Therapeutics announced that the US FDA has approved a new drug clinical trial application (IND) for the allogeneic CAR-T cell therapy P-MUC1C-ALLO1 to treat multiple solid tumor indications .
-
She removed her left kidney due to cancer to save her test but discovered the secret to the treatment of kidney cancer
Time of Update: 2021-11-15
The difference in different tumor samples tells them that whether patients can respond to immunotherapy largely depends on whether such T cell receptors exist in their bodies before treatment .
-
Roche and CombiGene sign an agreement to develop AAV gene therapy for the treatment of drug-resistant epilepsy
Time of Update: 2021-11-05
Recent popular reports from Yimaike ★Medical ClassApplication and prospects of CAR-T cell technology in the functional cure of AIDS EMedClub PR News/--Recently, Roche's gene therapy company Spark Therapeutics and Swedish gene therapy company CombiGene announced the signing of an exclusive cooperation and licensing agreement for the CG01 project, a project designed to treat drug-resistant focal epilepsy Research-based gene therapy .
-
Tasly's subsidiary bezafibrate sustained-release tablets and temozolomide for injection obtained drug registration certificates
Time of Update: 2021-11-04
On October 21, Tasly issued an announcement stating that its subsidiaries, bezafibrate sustained-release tablets and temozolomide for injection, have obtained drug registration certificates .
Sustained-release bezafibrate tablets are used to treat adult hypertriglyceridemia and mixed hyperlipidemia .
-
Hengrui Medicine's 1.3 billion innovative drug Punaburin will be another wealth code
Time of Update: 2021-10-22
Figure 2 The inhibitory activity of punabulin on tumor cell lines and drug-resistant tumor cell linesIn 2011, Professor Hayashi summarized the structure-activity relationship of punabrine modified by phenylahistin (see Figure 3): 1.
-
[JMC] You Qidong/Wang Lei, etc.: Research progress of small molecule targeting serine protein phosphatase (PPPases
Time of Update: 2021-08-08
Although they play a common mechanism of dephosphorylation through highly conserved catalytic active sites, different pppases show specificity according to their different regulatory subunits or unique structural features, which provides potential for the rational design of small molecules.
-
Innomicropharmaceuticals MVR-T3011 (intratumor injection) clinical phase II first case of drug delivery completed simultaneously in China and the United States
Time of Update: 2021-06-22
Innomicropharmaceuticals announced that its leading oncolytic virus product MVR-T3011 intratumoral injection (MVR-T3011 IT) phase II clinical study will be completed on May 28 and June 11, 2021, in China and the United States, respectively.
